Does Rallies show Form 4 insider transactions for BRTX?

Yes. Rallies tracks BRTX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is BRTX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BRTX. It does not provide personalized investment advice.

BRTX (BioRestorative Therapies, Inc. Common Stock (NV)) Stock Analysis - Insider Trades

BioRestorative Therapies, Inc. Common Stock (NV) (BRTX) is a publicly traded Healthcare sector company. As of May 21, 2026, BRTX trades at $0.17 with a market cap of $4.75M and a P/E ratio of -0.11. BRTX moved -7.84% today. Year to date, BRTX is -85.80%; over the trailing twelve months it is -89.15%. Its 52-week range spans $0.16 to $2.55. Analyst consensus is buy with an average price target of $8.00. Rallies surfaces BRTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading BRTX stock inside the company?

Recent BRTX insider activity includes Broadrick Dale sold 1.11K, Silva Francisco bought 6.60K, Silva Francisco bought 476, Silva Francisco bought 1.23K, and Broadrick Dale bought 86.04K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

BRTX Key Metrics

Key financial metrics for BRTX
Metric	Value
Price	$0.17
Market Cap	$4.75M
P/E Ratio	-0.11
EPS	$-1.58
Dividend Yield	0.00%
52-Week High	$2.55
52-Week Low	$0.16
Volume	79.09K
Avg Volume	0
Revenue (TTM)	$359.70K
Net Income	$-14.24M
Gross Margin	93.37%

Recent BRTX Insider Trades

Broadrick Dale sold 1.11K (~$1.76K) on Oct 28, 2024.
Silva Francisco bought 6.60K (~$8.25K) on Apr 9, 2024.
Silva Francisco bought 476 (~$537.88) on Apr 8, 2024.
Silva Francisco bought 1.23K (~$1.44K) on Apr 8, 2024.
Broadrick Dale bought 86.04K (~$113.57K) on Feb 9, 2024.

Latest BRTX News

BioRestorative Therapies Unveils MSC Exosome Proteomics from Cord, Adipose, Bone Marrow Enabling Targeted Regenerative, Aesthetic Applications — May 13, 2026
BioRestorative’s BRTX-100 Phase 2 Shows 52% ≥50% Pain and Function Gain in 25 Patients — May 7, 2026
BioRestorative to reveal Phase 2 lumbar disc safety data and exosome proteomics — Apr 30, 2026
BioRestorative Teams with 203 Creates to Launch BioX™ Platform Globally — Apr 7, 2026
BioRestorative Reports 75% Pain Relief at 52 Weeks, No Safety Events — Mar 30, 2026

BRTX Analyst Consensus

2 analysts cover BRTX: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $8.00.

Common questions about BRTX

Who is trading BRTX stock inside the company?: Recent BRTX insider activity includes Broadrick Dale sold 1.11K, Silva Francisco bought 6.60K, Silva Francisco bought 476, Silva Francisco bought 1.23K, and Broadrick Dale bought 86.04K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for BRTX?: Yes. Rallies tracks BRTX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is BRTX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BRTX. It does not provide personalized investment advice.